Ono Pharmaceutical Co., Ltd. (OPHLF) Stock Price & Analysis
Ono Pharmaceutical Co., Ltd. (OPHLF) closed at USD 15.3 on Wednesday, October 21, 2026, up 0.92% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 15.16; the Oct 21, 2026 session ranged USD 15.3–15.3 on volume of 625 shares. Market capitalization is $7.19B, with a 52-week range of USD 11.08–18.67 (PNK). Source: Nexqual, retrieved October 23, 2026 at 16:39 UTC.
Also available as compact Markdown for AI agents: nexqual.com/OPHLF.md
Key facts (OPHLF)
- Analysts: None.
- Total return with dividends: 1Y +30.7% vs S&P 500 +14.6%; 5Y +26.7% vs S&P 500 +77.3%.
- Next earnings: 2026-10-29, EPS estimate USD —, revenue estimate $117B.
Analysts (OPHLF)
Consensus None.
Total return (dividends reinvested) (OPHLF)
| 1Y (from 2025-10-23) | 5Y (from 2024-08-12) | |
|---|---|---|
| Total return | +30.7% | +26.7% |
| S&P 500 (SPY) | +14.6% | +77.3% |
| Per year | +30.9% | +11.4% |
| Volatility (annualized) | 45.7% | 51.6% |
| Max drawdown | -27.0% (Feb 2026→Jul 2026) | -39.4% (Sep 2024→Jan 2025) |
OPHLF analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | — | — | — | $116.61B | — |
| Next quarter (ends Dec 2026) | — | — | — | $122.00B | — |
| Current fiscal year (ends Mar 2027) | — | — | — | $460.91B | — |
| Next fiscal year (ends Mar 2028) | — | — | — | $448.89B | — |
Key Statistics (as of October 23, 2026 at 16:39 UTC)
| Price | USD 15.3 |
|---|---|
| Change | ▲ 0.92% (up) |
| Previous Close | USD 15.16 |
| Open | USD 15.3 |
| Day Range | USD 15.3 – 15.3 |
| 52-Week Range | USD 11.08 – 18.67 |
| Volume | 625 shares |
| Market Cap | $7.19B |
| Exchange | PNK |
Technical Analysis (OPHLF)
Nexqual's technical model rates OPHLF "BUY" based on 4 bullish and 2 bearish signals across 127 daily candles, as of October 23, 2026 at 16:39 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 55.18 (neutral) |
| vs SMA50 | Above (USD 15.18) |
| MACD | 0 (positive) |
Analyst Ratings (OPHLF)
Wall Street analysts rate OPHLF "None", per Nexqual as of October 23, 2026 at 16:39 UTC.
| Consensus Rating | None |
|---|
Earnings (OPHLF)
| Next Earnings Date | 2026-10-29 |
|---|---|
| Revenue Estimate | $116.61B |
Source: Nexqual, October 23, 2026 at 16:39 UTC.
Financials & Fundamentals (OPHLF)
| Total Revenue | $504.41B |
|---|---|
| Revenue Growth (latest quarter, YoY) | -8.90% |
| Gross Margin | +73.56% |
| Operating Margin | +26.39% |
| Profit Margin | +15.12% |
| ROE | +9.26% |
| Debt / Equity | 0.13 |
| Current Ratio | 3.28 |
| Total Cash | $219.62B |
| Total Debt | $117.10B |
Source: Nexqual, October 23, 2026 at 16:39 UTC.
Financial Health Score (OPHLF)
Nexqual rates Ono Pharmaceutical Co., Ltd.'s overall financial health "Solid" across five dimensions, as of October 23, 2026 at 16:39 UTC.
| Growth | Solid — Revenue +6% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 74%, operating 26% (last 12 months) |
| Balance Sheet | Strong — JPY 219.6B cash vs JPY 117.1B debt, net cash position |
| Cash Flow | Solid — Operating cash flow JPY 134.5B (TTM) |
| Efficiency | Mixed — ROE 9%, ROA 6.0% |
Ownership (OPHLF)
| Insider Ownership | +11.99% |
|---|---|
| Institutional Ownership | +40.49% |
| Shares Outstanding | 469.91M |
| Float | 453.49M |
Source: Nexqual, October 23, 2026 at 16:39 UTC.
Leadership (OPHLF)
Ono Pharmaceutical Co., Ltd. is led by Gyo Sagara, CEO & Chairman of the Board, per Nexqual as of October 23, 2026 at 16:39 UTC.
| CEO & Chairman of the Board | Gyo Sagara |
|---|---|
| President, COO & Representative Director | Toichi Takino |
| Vice President of Corporate Communications | Ryuta Imura |
| Corporate Officer and Executive Director of Discovery & Research | Seishi Katsumata |
| Vice President of Sustainability Promotion & Corporate Officer | Satoshi Takahagi |
Major Backers & Investors (OPHLF)
Notable institutional backers of Ono Pharmaceutical Co., Ltd. include Goldman Sachs, WisdomTree Trust-WisdomTree Japan Hedged Equity Fund, Old Westbury Funds Inc-Old Westbury Small & Mid Cap Strategies Fund, according to Nexqual as of October 23, 2026 at 16:39 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Goldman Sachs | 0.25% |
| WisdomTree Trust-WisdomTree Japan Hedged Equity Fund | 0.23% |
| Old Westbury Funds Inc-Old Westbury Small & Mid Cap Strategies Fund | 0.22% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 2.14% |
| BlackRock | 1.2% |
| Dimensional Fund Advisors | 0.36% |
Source: Nexqual, October 23, 2026 at 16:39 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| GRFS | Grifols, S.A. | USD 7.55 | ▲ 1.28% |
| OGN | Organon & Co. | USD 13.76 | ▲ 0.07% |
| BIIB | Biogen Inc. | USD 250.76 | ▼ 1.21% |
| SNY | Sanofi | USD 41.48 | ▼ 1.14% |
| GSK | GSK plc | USD 50.61 | ▼ 1.18% |
| BMY | Bristol-Myers Squibb Company | USD 61.76 | ▼ 1.98% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 16:39 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt